Abbott has received FDA authorization for its Libre Duo 10 Day system, the world's first biowearable device that continuously monitors both glucose and ketone levels. This innovation helps people with diabetes detect rising ketones early, which can prevent diabetic ketoacidosis (DKA), a serious and potentially life-threatening condition. The device integrates with Abbott's Libre app and is compatible with automated insulin delivery systems. Abbott plans to launch the product in the U.S. later this year, aiming to improve diabetes management by providing real-time alerts without added burden on users.
Abbott received FDA De Novo authorization for Libre Duo 10 Day, the first wearable device that continuously monitors glucose and detects rising ketone levels, which can signal diabetic ketoacidosis. This regulatory milestone sets Abbott apart in diab...
Abbott has received CE Mark approval for its Amulet 360 Left Atrial Appendage Occluder, a next-generation device designed to reduce stroke risk in patients with atrial fibrillation (AFib) by sealing the heart's left atrial appendage (LAA). The device...
Retirees choosing between Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Real Estate ETF (VNQ) face a clear divergence due to the current high interest rate environment. SCHD, focused on dividend-paying companies with strong cash flow, has outpe...
